Literature DB >> 20384534

Dengue vaccines: state of the art.

Sathyamangalam Swaminathan1, Gaurav Batra, Navin Khanna.   

Abstract

IMPORTANCE OF THE FIELD: Dengue is a significant public health problem transcending geographical boundaries to place nearly 50% of the global population at risk. A vaccine to prevent dengue is an unmet need that should be addressed urgently. AREAS COVERED IN THE REVIEW: A brief introduction to dengue and a detailed review of the classical and modern approaches being undertaken currently to develop dengue vaccines described in recent patent literature, highlighting the inherent hurdles and challenges. WHAT THE READER WILL GAIN: An understanding of the approaches being deployed to develop multiple viral and non-viral vaccine candidates and an appreciation of the complexity of developing dengue vaccines. TAKE HOME MESSAGE: Live viral vaccines, which have advanced to clinical trials, have revealed new challenges, emphasizing the need to pursue non-viral alternatives simultaneously.

Mesh:

Substances:

Year:  2010        PMID: 20384534     DOI: 10.1517/13543771003767476

Source DB:  PubMed          Journal:  Expert Opin Ther Pat        ISSN: 1354-3776            Impact factor:   6.674


  22 in total

1.  M cell-targeting ligand and consensus dengue virus envelope protein domain III fusion protein production in transgenic rice calli.

Authors:  Tae-Geum Kim; Mi-Young Kim; Nguyen-Xuan Huy; Sae-Hae Kim; Moon-Sik Yang
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

2.  Hospital-based prevalence of malaria and dengue in febrile patients in Bangladesh.

Authors:  Labib I Faruque; Rashid Uz Zaman; A S M Alamgir; Emily S Gurley; Rashidul Haque; Mahmudur Rahman; Stephen P Luby
Journal:  Am J Trop Med Hyg       Date:  2012-01       Impact factor: 2.345

3.  Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies.

Authors:  Niyati Khetarpal; Rahul Shukla; Ravi Kant Rajpoot; Ankur Poddar; Meena Pal; Sathyamangalam Swaminathan; Upasana Arora; Navin Khanna
Journal:  Am J Trop Med Hyg       Date:  2016-11-07       Impact factor: 2.345

4.  Issues related to recent dengue vaccine development.

Authors:  Eiji Konishi
Journal:  Trop Med Health       Date:  2011-08-06

5.  Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement.

Authors:  Holly R Hughes; Wayne D Crill; Gwong-Jen J Chang
Journal:  Virol J       Date:  2012-06-18       Impact factor: 4.099

6.  Dengue, Urbanization and Globalization: The Unholy Trinity of the 21(st) Century.

Authors:  Duane J Gubler
Journal:  Trop Med Health       Date:  2011-08-25

7.  Adenovirus delivered short hairpin RNA targeting a conserved site in the 5' non-translated region inhibits all four serotypes of dengue viruses.

Authors:  Anil Babu Korrapati; Gokul Swaminathan; Aarti Singh; Navin Khanna; Sathyamangalam Swaminathan
Journal:  PLoS Negl Trop Dis       Date:  2012-07-24

8.  Dengue-specific subviral nanoparticles: design, creation and characterization.

Authors:  Niyati Khetarpal; Ankur Poddar; Satish K Nemani; Nisha Dhar; Aravind Patil; Priyanka Negi; Ashiya Perween; Ramaswamy Viswanathan; Heinrich Lünsdorf; Poornima Tyagi; Rajendra Raut; Upasana Arora; Swatantra K Jain; Ursula Rinas; Sathyamangalam Swaminathan; Navin Khanna
Journal:  J Nanobiotechnology       Date:  2013-05-25       Impact factor: 10.435

9.  Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titer neutralizing antibodies.

Authors:  Shailendra Mani; Lav Tripathi; Rajendra Raut; Poornima Tyagi; Upasana Arora; Tarani Barman; Ruchi Sood; Alka Galav; Wahala Wahala; Aravinda de Silva; Sathyamangalam Swaminathan; Navin Khanna
Journal:  PLoS One       Date:  2013-05-23       Impact factor: 3.240

10.  Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2.

Authors:  Upasana Arora; Poornima Tyagi; Sathyamangalam Swaminathan; Navin Khanna
Journal:  J Nanobiotechnology       Date:  2012-07-13       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.